Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
Start of Day Message
-
BNP PARIBAS : BNP PARIBAS GROUP SELLS ITS STAKE IN AG INSURANCE AND FORMALISES LONG TERM PARTNERSHIP WITH AGEAS
-
Ageas to take full ownership of AG Insurance and formalise long term partnership with BNP Paribas
-
YAS Healthcare signs contract for a Proteus®ONE solution, the first proton therapy system to be installed in Dubai, UAE
-
NOTICE TO DISREGARD -- ICARO Media Group
-
SED Initta and Intel Deepen Strategic Partnership to Accelerate AI-Driven Retail Transformation
-
HVAC Expert Ben Fleck of Gretna Advises Homeowners to Change Air Filters Regularly in HelloNation
-
Pest Control Expert Steven Moore of Port Washington Shares The Top 4 Household Pests for HelloNation
-
Collision Repair Expert Andy Spence of Jackson, TN, Explains Why Certified Collision Repair Matters for HelloNation
-
Retail Expert Melissa Skelton Shares Insights on Custom vs. Commercial Easter Gifts in New HelloNation Feature
-
Laser Hair Removal Expert Dr. Terese Thomas, MD Explains Sublative Radiofrequency vs Facial in HelloNation
-
Marine Transport Expert Jon Arrigoni of Arrigoni Marine Movers Warns Boat Owners About Insurance Gaps in HelloNation
-
Cochin Shipyard to build next-generation electric TRAnsverse tugs for Svitzer
-
HeroFlow Announces Expansion of Access to “The AI Employee,” the 24/7 Virtual Receptionist That Never Calls In Sick
-
Faraday Future Founder and Co-CEO YT Jia Shares Weekly Investor Update: The FX Super One First Pre-Production Vehicles Roll-off Ceremony is Scheduled for December 21 at the Company’s Hanford, CA Fac
-
The Ohio State University’s Caleb Downs Named Winner of Lott IMPACT Trophy Presented by Allied Universal
-
OPay Appoints Former Citigroup Managing Director James Perry as CFO
-
ASH 2025 | Ascentage Pharma Presents Encouraging Data from Phase Ib/II Study of Bcl-2 Inhibitor Lisaftoclax in Venetoclax–Exposed Patients with Myeloid Malignances
-
Skyline Digital Marketing Introduces Proprietary Skyline Methodology to Strengthen Data-Driven Business Growth
-
HUTCHMED Announces Expanded Coverage on National Reimbursement Drug List and Inclusion in the First Commercial Insurance Drug List in China
-
Structure Therapeutics to Report Data from ACCESS Clinical Program of Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron, on December 8, 2025
-
Immix Biopharma Announces Pricing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
-
At ASH 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 NXC-201 Results, Advancing Toward BLA Submission as a Potentially First- and Best-in-Class Therapy for relapsed/refractory AL Am
-
SELLAS Life Sciences Presents Positive Phase 2 Data of SLS009 in Combination with AZA/VEN in Relapsed/Refractory AML-MR at ASH 2025
-
Lime & Lemon Apex Redefines the Dining Scene with an Experience the Triangle Was Waiting For
-
Lime & Lemon Apex Redefines the Dining Scene with an Experience the Triangle Was Waiting For
-
ImCheck Reports Durable Responses and Early Overall Survival Signal with ICT01 in First-line AML at ASH 2025
-
Miltenyi Biomedicine presents primary analysis of the pivotal DALY 2-EU trial for second-line relapsed/refractory large B-cell lymphoma at the 67th American Society of Hematology (ASH) Annual Meeting
-
Drilling hits wide zone of mineralisation in new area well outside resource
-
Lynozyfic™ (linvoseltamab) Monotherapy in Newly Diagnosed Multiple Myeloma (NDMM) Shows Impressive Responses, Supporting Rationale as a Potential Foundation in Frontline Treatment
-
Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and
-
Wave Life Sciences to Announce Interim Data from the Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity on Monday, December 8, 2025
-
Rally House Breaks Company Online Sales Record After Electric Sports Weekend
-
Dyne Therapeutics to Host Investor Conference Call and Webcast to Review Topline Results from Registrational Expansion Cohort (REC) of DELIVER Clinical Trial of Z-Rostudirsen (DYNE-251) in Duchenne Mu
-
Nayax Considering an Offering of Notes and Warrants in Israel
-
Real Estate Expert Kerry Ramage of Melbourne, FL, Breaks Down Home Sale Strategy for HelloNation
-
Prime Medicine Announces The New England Journal of Medicine Publication of PM359 Clinical Data for the Treatment of Chronic Granulomatous Disease
-
Secura Bio Presents Extended Follow Up Analyses from Phase 2 PRIMO Trial in Patients with Relapsed/Refractory peripheral T-cell lymphoma at the 2025 American Society of Hematology Meeting
-
Mutuum Finance (MUTM) Approaches 100% Presale Sellout Amid Ongoing Halborn Security Review
-
ALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with Indolent B-cell Non-Hodg
-
Manufacturing Expert James Gizzi of Rochester Discusses How to Choose a CNC Machine Shop in HelloNation
-
Genmab Presents Pivotal Phase 3 Data from EPCORE® FL-1 Trial Demonstrating Clinical Benefit of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide (R2) in Patients with Relaps
-
How Roofing Expert Tom Meadows of Ann Arbor Explains Roof Repair vs. Roof Replacement for HelloNation
-
Molecular Partners Presents Updated Data from Ongoing Phase 1/2a Trial of MP0533 in AML at ASH Annual Meeting
-
New Crypto Mutuum Finance Completes Phase 1 Roadmap Milestones, Builds Momentum Into Phase 2
-
2025 "Silk Road for All Children" International Children's Literature Week The 10th Fairy Tales Conference Held in Wuyi, China
-
Funding Reaches $19.2M as Mutuum Finance (MUTM) Presale Moves Toward Full Allocation
-
SALI Showcases Global Ambition with Times Square Billboard Campaign, Marking a New Milestone in Its Journey Toward a Global Power Tool Accessories Empire
-
TScan Therapeutics Announces Positive Updated Data from the ALLOHA™ Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition
-
Fulcrum Therapeutics Announces Positive Initial Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual M
